| Heading: |
Cannabis: Medical Treatments |
| Question ID: |
1817168 |
| UIN: |
63155 |
| House: |
Commons |
| Date tabled: |
2025-06-26 |
| Asking Member ID: |
5201 |
| Asking Member display name: |
Victoria Collins
|
| Asking Member handle: |
TweetingCollins
|
| Asking Member Twitter reference: |
@TweetingCollins
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of permitting GPs to prescribe cannabis-based medicinal products; and what plans he has to ensure NHS access to full-spectrum cannabi |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-07-04 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The conditions attached to a medicine’s marketing authorisation determine who it can be prescribed by. This may include restricting the initiation of treatments to specialist doctors, as is the case for the licensed cannabis-based medicines Sativex and Ep... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |